Healthcare
Fund focus: Emphasizing the partnership approach
Having raised $250 million for its third India healthcare fund, Invascent Capital plans to take advantage of a greater willingness among entrepreneurs to work with financial investors
GIC leads $125m round for China cancer diagnostics business
GIC Private has led a RMB850 million ($125.5 million) Series C round for Burning Rock, a Chinese cancer diagnostics start-up that is already working with hospitals on products based on DNA sequencing analysis.
Legend leads $29m round for Chinese biotech player
Sciwind Biosciences, a Chinese drug developer focused on treating metabolic disorders, has raised RMB200 million ($29 million) in Series A funding led by Legend Capital, with participation from existing investors Shiyu Capital and Beijing-based biotech...
New Zealand’s Direct Capital invests retirement village operator
New Zealand’s Direct Capital has acquired a minority stake in local retirement village operator Qestral Corporation for an undisclosed sum.
Temasek invests $38m in India eye hospital chain
Singapore’s Temasek Holdings has invested INR 2.7 billion ($38.1 million) in India's Dr. Agarwal’s Healthcare to support the expansion of its publicly listed eyecare chain Dr. Agarwal’s Eye Hospital.
Vision Knight backs Chinese personal care products maker
Vision Knight Capital has led a RMB200 million ($29 million) Series C round for Soocas, a Shenzhen-based manufacturer of personal care products such as electric toothbrushes and hairdryers.
C-Bridge helps Korea's Samsung Bioepis with China expansion
C-Bridge Capital has announced a licensing agreement with Samsung Bioepis that is intended to help the Korean biopharmaceutical specialist expand into the China market.
Huagai leads $146m round for China’s HaiHe Biopharma
Shanghai-based cancer drug developer HaiHe Biopharma has raised $146.6 million in a funding round led by Chinese private equity firm Huagai Capital.
Japan's J-Will set for $272m buyout of ND Software
J-Will Partners has won board support for its proposed acquisition of ND Sofware, a Japanese software developer that serves the healthcare sector, through a tender offer at a valuation of JPY29.9 billion ($272 million).
IDG, Lilly join $10m round for China’s EdiGene
IDG Capital and Lilly Asia Ventures (LAV) have joined a $10 million investment in EdiGene, a developer of genetics-based therapies based in Beijing.
TPG Growth invests $30m in Indian pharma player
TPG Growth, the mid-market investment platform of TPG Capital, has invested $30 million in Indian pharmaceutical ingredient maker Solara Active Pharma.
Australia's Healthscope agrees $3.17b Brookfield bid
Australia-listed hospital operator Healthscope has agreed to a take-private offer by Brookfield Asset Management that values the company at A$4.38 billion ($3.17 billion) on an equity basis, rejecting a competing offer from a consortium led by BGH Capital.
Invascent closes India healthcare fund at $250m hard cap - update
Invascent Capital, an Indian healthcare-focused GP, has closed its third vehicle at the hard cap of $250 million.
Eight Roads leads $6.3m round for India pharma player
Ashish Life Science, an Indian producer of generic pharmaceuticals for the international veterinary market, has raised a INR450 million ($6.3 million) Series A round led by Eight Roads Ventures India.
Deal focus: Advent sees potential in hybrid CRO
Advent International recognized BioDuro as a company uniquely positioned to leverage growth in pharmaceutical R&D outsourcing in China and the US
Advent buys majority stake in US, China-based BioDuro
Advent International has acquired a majority stake in BioDuro, a pharmaceutical contract research and development organization (CRO) with operations in the US and China, from the Bridgewest Group conglomerate.
China's Gobi makes its first two Philippines investments
China’s Gobi Partners has made its first investments in the Philippines with early-stage commitments of undisclosed size for online healthcare services provider Maria Health and student portal operator Edukasyon.
Immunochina secures $20.5m Series C round
Beijing-based Immunochina Pharmaceuticals has closed a RMB140 million ($20.5 million) Series C round with support from a group of investors including PayPal co-founder Peter Thiel.
Shanghai launches $7.35b biotech fund
The Shanghai government has launched a biotech sector-focused fund targeting a hard cap of RMB50 billion ($7.35 billion) in partnership with Guotai Junan Securities, China Pacific Insurance and Shanghai Zhangjiang Group.
China’s MabPlex raises $59m Series A
Shandong province-based biologics and biopharmaceutical contract development and manufacturing organization (CDMO) MabPlex has raised RMB400 million ($59 million) in Series A funding led by SDIC Venture Capital and Shenzhen Capital Group.
Eight Roads invests $31m in Indian pharma player
Eight Roads Ventures, the proprietary investment arm of Fidelity International, has invested INR2.18 billion ($30.6 million) in Indian pharmaceutical manufacturer Caplin Point. Sister fund F-Prime Capital Ventures also participated.
Suning invests in Yunfeng co-invest vehicle for iKang take-private
Chinese consumer electronics retailer Suning has committed $50 million to a US dollar-denominated co-investment vehicle managed by Yunfeng Capital that will support the $1.4 billion privatization of iKang Healthcare Group.
Deal focus: Medbanks brings big data to China cancer care
Medbanks raises a $59 million Series C round to update the traditional information networks that make China’s growing oncology industry tick. Quality of management has proven a critical investment factor
Chinese eye hospital chain Chaoju raises $59m
Chinese eye hospital chain operator Chaoju Ophthalmology has raised RMB400 million ($59 million) in a Series B round of funding backed by Orchid Asia Group and River Head Capital.